Catalent announces new business unit, audit completion

Catalent Pharma Solutions appointed Scott Houlton as group president for a new business unit called the Development and Clinical Services segment.

The new segment brings together the company's analytical and science services and regulatory consulting services, formerly its Sterile Technologies segment, with its clinical supply services, formerly included in the Packaging Services segment. The new segment will support the development and testing of drugs and biologics through scientific, regulatory, and clinical trial supply chain services. Separately, the company announced the completion of the first FDA general cGMP audit and pre-approval inspection of its Buenos Aires, Argentina pharmaceutical softgel facility, with no reported observations on FDA Form 483.
Companies in this article
More in Home